WallStSmart

Artivion Inc (AORT)vsStryker Corporation (SYK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 5358% more annual revenue ($26.30B vs $481.88M). SYK leads profitability with a 13.8% profit margin vs -3.6%. SYK appears more attractively valued with a PEG of 1.37. SYK earns a higher WallStSmart Score of 57/100 (C).

AORT

Hold

35

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 3.0Quality: 6.5
Piotroski: 4/9Altman Z: 1.46

SYK

Buy

57

out of 100

Grade: C

Growth: 5.3Profit: 7.5Value: 4.0Quality: 6.5
Piotroski: 2/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AORTSignificantly Overvalued (-28.3%)

Margin of Safety

-28.3%

Fair Value

$31.25

Current Price

$19.40

$11.85 premium

UndervaluedFair: $31.25Overvalued
SYKSignificantly Overvalued (-38.2%)

Margin of Safety

-38.2%

Fair Value

$235.85

Current Price

$318.79

$82.94 premium

UndervaluedFair: $235.85Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AORT1 strengths · Avg: 8.0/10
Price/BookValuation
2.1x8/10

Reasonable price relative to book value

SYK3 strengths · Avg: 8.3/10
Market CapQuality
$111.11B9/10

Large-cap with strong market position

Operating MarginProfitability
20.3%8/10

Strong operational efficiency at 20.3%

Free Cash FlowQuality
$1.22B8/10

Generating 1.2B in free cash flow

Areas to Watch

AORT4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$998.73M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
4.9%3/10

Operating margin of 4.9%

PEG RatioValuation
181.502/10

Expensive relative to growth rate

SYK3 concerns · Avg: 3.0/10
P/E RatioValuation
31.1x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-11.7%2/10

Earnings declined 11.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : AORT

The strongest argument for AORT centers on Price/Book.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap, Operating Margin, Free Cash Flow. PEG of 1.37 suggests the stock is reasonably priced for its growth.

Bear Case : AORT

The primary concerns for AORT are EPS Growth, Market Cap, Operating Margin.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

AORT profiles as a turnaround stock while SYK is a value play — different risk/reward profiles.

AORT carries more volatility with a beta of 1.28 — expect wider price swings.

AORT is growing revenue faster at 9.2% — sustainability is the question.

SYK generates stronger free cash flow (1.2B), providing more financial flexibility.

Bottom Line

SYK scores higher overall (57/100 vs 35/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Artivion Inc

HEALTHCARE · MEDICAL DEVICES · USA

Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?